Misonidazole neuropathy: A clinical, electrophysiological and histological study

Melgaard, B; Hansen, Hanne Sand; Kamieniecka, Z; Paulson, Olaf B.; Pedersen, Anders; Tang, Xiaolin; Trojaborg, W.

doi:10.1002/ana.410120103

Cited by 25 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Energy metabolism-related deficits were predicted in the early 1980’s following observations of excessive weight loss and deficient brain FDG uptake on PET (Sanberg et al, 1981; Kuhl et al, 1982). In the early 1990’s proton nuclear magnetic resonance spectroscopy further revealed increased lactate in the cortex and basal ganglia of HD subjects (Jenkins et al, 1993).…”

Section: Huntington’s Diseasementioning

confidence: 99%

Mitochondria in Neurodegeneration

Lezi

Swerdlow

2011

Advances in Experimental Medicine and Biology

179

129

View full text Add to dashboard Cite

Many neurodegenerative diseases demonstrate abnormal mitochondrial morphology and biochemical dysfunction. Alterations are often systemic rather than brain-limited. Mitochondrial dysfunction may arise as a consequence of abnormal mitochondrial DNA, mutated nuclear proteins that interact directly or indirectly with mitochondria, or through unknown causes. In most cases it is unclear where mitochondria sit in relation to the overall disease cascades that ultimately causes neuronal dysfunction and death, and there is still controversy regarding the question of whether mitochondrial dysfunction is a necessary step in neurodegeneration. In this chapter we highlight and catalogue mitochondrial perturbations in some of the major neurodegenerative diseases including Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington’s disease (HD). We consider data that suggest mitochondria may be critically involved in neurodegenerative disease neurodegeneration cascades.

show abstract

Section: Huntington’s Diseasementioning

confidence: 99%

Mitochondria in Neurodegeneration

Lezi

Swerdlow

2011

Advances in Experimental Medicine and Biology

179

129

View full text Add to dashboard Cite

show abstract

“…25 Immunosuppressive medications. It appears to act on multiple myeloma by inhibiting NF.B activation.…”

Section: Case 7-1mentioning

confidence: 99%

Medication, Toxic, and Vitamin-Related Neuropathies

Morrison

Chaudhry²

2012

CONTINUUM: Lifelong Learning in Neurology

View full text Add to dashboard Cite

show abstract

“…Use of MISO in patients undergoing radiation therapy is limited primarily by the onset of a peripheral sensory neuropathy (10,13) that usually appears after administration of total doses higher than approximately 12 g/m 2 (1,2,13). Use of MISO in patients undergoing radiation therapy is limited primarily by the onset of a peripheral sensory neuropathy (10,13) that usually appears after administration of total doses higher than approximately 12 g/m 2 (1,2,13).…”

Section: Introductionmentioning

confidence: 99%

Misonidazole neurotoxicity in rats: Part I

Edwards¹,

Gordon²,

Levin³

et al. 1984

J Neuro-Oncol

View full text Add to dashboard Cite

The effects of misonidazole (MISO) on brain stem evoked potentials (BAEPs) and cortical evoked potentials (CEPs) were evaluated in 16 Sprague-Dawley rats !reated with the agent. As found in previous studies, serial BAEPvalues were diagnostic of the onset of MISO toxicity before clinical signs and symptoms appeared. However, MISO had no effects on CEPs, which remained essentially unchanged through the course of the experiment. At histologic examination, significant changes were found in the area of the brain stem, but there was no histologic evidence of damage to cortical or subcortical structures caused by MISO administration. The results of this study suggest that the neurotoxic effects of MISO are species-specific, and that while the rat model may be useful for comparison of the relative toxic effects of nitroimidazole radiosensitizers, it is not a model suited for measurement of neurotoxicity caused by MISO in humans and nonhuman primates.A ddressfor reprints: Dr Edwards, c/o the Editorial Office,

show abstract

Misonidazole neuropathy: A clinical, electrophysiological and histological study

Cited by 25 publications

References 18 publications

Mitochondria in Neurodegeneration

Mitochondria in Neurodegeneration

Medication, Toxic, and Vitamin-Related Neuropathies

Misonidazole neurotoxicity in rats: Part I

Contact Info

Product

Resources

About